Molecularly defined sinonasal malignancies: an overview with focus on the current WHO classification and recently described provisional entities.
Head and neck
Molecular diagnostics
Next-generation sequencing
Sinonasal
Sinonasal tumor
Soft tissue
Journal
Virchows Archiv : an international journal of pathology
ISSN: 1432-2307
Titre abrégé: Virchows Arch
Pays: Germany
ID NLM: 9423843
Informations de publication
Date de publication:
16 Mar 2024
16 Mar 2024
Historique:
received:
06
01
2024
accepted:
04
03
2024
revised:
19
02
2024
medline:
16
3
2024
pubmed:
16
3
2024
entrez:
16
3
2024
Statut:
aheadofprint
Résumé
Classification of tumors of the head and neck has evolved in recent decades including a widespread application of molecular testing in tumors of the sinonasal tract, salivary glands, and soft tissues with a predilection for the head and neck. The availability of new molecular techniques has allowed for the definition of multiple novel tumor types unique to head and neck sites. Moreover, an expanding spectrum of immunohistochemical markers specific to genetic alterations facilitates rapid identification of diagnostic molecular abnormalities. As such, it is currently possible for head and neck pathologists to benefit from a molecularly defined tumor classification while making diagnoses that are still based largely on histopathology and immunohistochemistry. This review covers the principal molecular alterations in sinonasal malignancies, such as alterations in DEK, AFF2, NUTM1, IDH1-2, and SWI/SNF genes in particular, that are important from a practical standpoint for diagnosis, prognosis, and prediction of response to treatment.
Identifiants
pubmed: 38491228
doi: 10.1007/s00428-024-03775-y
pii: 10.1007/s00428-024-03775-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
WHO Classification of Tumours Editorial Board. Head and neck tumours. Lyon (France): International Agency for Research on Cancer; forthcoming. (WHO classification of tumours series, 5th edn, vol 9). https://publications.iarc.fr
Chatelet F, Simon F, Bedarida V, Le Clerc N, Adle-Biassette H, Manivet P, Herman P, Verillaud B (2021) Surgical management of sinonasal cancers: a comprehensive review. Cancers (Basel) 13(16):3995. https://doi.org/10.3390/cancers13163995
Bossi P, Orlandi E, Resteghini C et al (2023) The SINTART 2 study. A phase II non-randomised controlled trial of induction chemotherapy, photon-, proton- and carbon-ion-based radiotherapy integration in patients with locally advanced unresectable sinonasal tumours. Eur J Cancer 187:134–143
pubmed: 37163806
doi: 10.1016/j.ejca.2023.03.034
Yang W, Lee KW, Srivastava RM et al (2019) Immunogenic neoantigens derived from gene fusions stimulate T cell responses. Nat Med 25:767–775
pubmed: 31011208
pmcid: 6558662
doi: 10.1038/s41591-019-0434-2
Todorovic E, Truong T, Eskander A et al (2020) Middle ear and temporal bone nonkeratinizing squamous cell carcinomas with DEK-AFF2 fusion: an emerging entity. Am J Surg Pathol 44:1244–1250
pubmed: 32366754
doi: 10.1097/PAS.0000000000001498
Ruangritchankul K, Sandison A (2023) DEK::AFF2 fusion carcinomas of head and neck. Adv Anat Pathol 30:86–94
pubmed: 36221219
doi: 10.1097/PAP.0000000000000376
Rooper LM, Agaimy A, Dickson BC et al (2021) DEK-AFF2 carcinoma of the sinonasal region and skull base: detailed clinicopathologic characterization of a distinctive entity. Am J Surg Pathol 45:1682–1693
pubmed: 34049316
doi: 10.1097/PAS.0000000000001741
Kuo YJ, Lewis JS Jr, Zhai C et al (2021) DEK-AFF2 fusion-associated papillary squamous cell carcinoma of the sinonasal tract: clinicopathologic characterization of seven cases with deceptively bland morphology. Mod Pathol 34:1820–1830
pubmed: 34108636
doi: 10.1038/s41379-021-00846-2
Bishop JA, Gagan J, Paterson C et al (2021) Nonkeratinizing squamous cell carcinoma of the sinonasal tract with DEK-AFF2: further solidifying an emerging entity. Am J Surg Pathol 45:718–720
pubmed: 33002918
doi: 10.1097/PAS.0000000000001596
Kuo YJ, Lewis JS Jr, Truong T et al (2022) Nuclear expression of AFF2 C-terminus is a sensitive and specific ancillary marker for DEK::AFF2 carcinoma of the sinonasal tract. Mod Pathol 35:1587–1595
pubmed: 35701667
doi: 10.1038/s41379-022-01117-4
Hellquist H, French CA, Bishop JA et al (2017) NUT midline carcinoma of the larynx: an international series and review of the literature. Histopathology 70:861–868
pubmed: 27926786
pmcid: 5386828
doi: 10.1111/his.13143
Chau NG, Ma C, Danga K et al (2020) An anatomical site and genetic-based prognostic model for patients with nuclear protein in testis (NUT) midline carcinoma: analysis of 124 patients. JNCI Cancer Spectr 4:pkz094
pubmed: 32328562
doi: 10.1093/jncics/pkz094
Haack H, Johnson LA, Fry CJ et al (2009) Diagnosis of NUT midline carcinoma using a NUT-specific monoclonal antibody. Am J Surg Pathol 33:984–991
pubmed: 19363441
pmcid: 2783402
doi: 10.1097/PAS.0b013e318198d666
Le Loarer F, Pissaloux D, Watson S et al (2019) Clinicopathologic features of CIC-NUTM1 sarcomas, a new molecular variant of the family of CIC-fused sarcomas. Am J Surg Pathol 43:268–276
pubmed: 30407212
doi: 10.1097/PAS.0000000000001187
Schaefer IM, Dal Cin P, Landry LM et al (2018) CIC-NUTM1 fusion: a case which expands the spectrum of NUT-rearranged epithelioid malignancies. Genes Chromosom Cancer 57:446–451
pubmed: 29700887
doi: 10.1002/gcc.3
French CA, Miyoshi I, Kubonishi I et al (2003) BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma. Cancer Res 63:304–307
pubmed: 12543779
Pivot-Pajot C, Caron C, Govin J et al (2003) Acetylation-dependent chromatin reorganization by BRDT, a testis-specific bromodomain-containing protein. Mol Cell Biol 23:5354–5365
pubmed: 12861021
pmcid: 165724
doi: 10.1128/MCB.23.15.5354-5365.2003
French CA, Ramirez CL, Kolmakova J et al (2008) BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells. Oncogene 27:2237–2242
pubmed: 17934517
doi: 10.1038/sj.onc.1210852
Huang QW, He LJ, Zheng S et al (2019) An overview of molecular mechanism, clinicopathological factors, and treatment in NUT carcinoma. Biomed Res Int 2019:1018439
pubmed: 31815119
pmcid: 6877965
doi: 10.1155/2019/1018439
French CA, Rahman S, Walsh EM et al (2014) NSD3-NUT fusion oncoprotein in NUT midline carcinoma: implications for a novel oncogenic mechanism. Cancer Discov 4:928–941
pubmed: 24875858
pmcid: 4125436
doi: 10.1158/2159-8290.CD-14-0014
Alekseyenko AA, Walsh EM, Zee BM et al (2017) Ectopic protein interactions within BRD4-chromatin complexes drive oncogenic megadomain formation in NUT midline carcinoma. Proc Natl Acad Sci U S A 114:E4184–E4192
pubmed: 28484033
pmcid: 5448232
doi: 10.1073/pnas.1702086114
Bauer DE, Mitchell CM, Strait KM et al (2012) Clinicopathologic features and long-term outcomes of NUT midline carcinoma. Clin Cancer Res 18:5773–5779
pubmed: 22896655
pmcid: 3473162
doi: 10.1158/1078-0432.CCR-12-1153
Cheng ML, Huang Y, Luong N et al (2023) Exceptional response to bromodomain and extraterminal domain inhibitor therapy with BMS-986158 in BRD4-NUTM1 NUT carcinoma harboring a BRD4 splice site mutation. JCO Precis Oncol 7:e2200633
pubmed: 37384867
doi: 10.1200/PO.22.00633
Ramesh U, Contrera KJ, Shakibai N et al (2024) Sinonasal NUT carcinoma: a consecutive case series and systematic review. Head Neck 46:29–36
pubmed: 37853958
doi: 10.1002/hed.27553
Filippakopoulos P, Qi J, Picaud S et al (2010) Selective inhibition of BET bromodomains. Nature 468:1067–1073
pubmed: 20871596
pmcid: 3010259
doi: 10.1038/nature09504
Tontsch-Grunt U, Traexler PE, Baum A et al (2022) Therapeutic impact of BET inhibitor BI 894999 treatment: backtranslation from the clinic. Br J Cancer 127:577–586
pubmed: 35444289
pmcid: 9346113
doi: 10.1038/s41416-022-01815-5
Wang X, Haswell JR, Roberts CW (2014) Molecular pathways: SWI/SNF (BAF) complexes are frequently mutated in cancer–mechanisms and potential therapeutic insights. Clin Cancer Res 20:21–27
pubmed: 24122795
doi: 10.1158/1078-0432.CCR-13-0280
Agaimy A, Koch M, Lell M et al (2014) SMARCB1(INI1)-deficient sinonasal basaloid carcinoma: a novel member of the expanding family of SMARCB1-deficient neoplasms. Am J Surg Pathol 38:1274–1281
pubmed: 24832165
pmcid: 4141899
doi: 10.1097/PAS.0000000000000236
Bishop JA, Antonescu CR, Westra WH (2014) SMARCB1 (INI-1)-deficient carcinomas of the sinonasal tract. Am J Surg Pathol 38:1282–1289
pubmed: 25007146
pmcid: 4134731
doi: 10.1097/PAS.0000000000000285
Agaimy A, Hartmann A, Antonescu CR et al (2017) SMARCB1 (INI-1)-deficient sinonasal carcinoma: a series of 39 cases expanding the morphologic and clinicopathologic spectrum of a recently described entity. Am J Surg Pathol 41:458–471
pubmed: 28291122
pmcid: 5354087
doi: 10.1097/PAS.0000000000000797
Agaimy A (2023) SWI/SNF-deficient sinonasal carcinomas. Adv Anat Pathol 30:95–103
pubmed: 36580412
doi: 10.1097/PAP.0000000000000372
Skálová A, Taheri T, Bradová M, Vaněček T, Franchi A, Slouka D, Kostlivý T, de Rezende G, Michálek J, Klubíčková N, Ptáková N, Nemcová A, Michal M, Agaimy A, Leivo I (2023) SMARCB1-deficient sinonasal adenocarcinoma: a rare variant of SWI/SNF-deficient malignancy often misclassified as high-grade non-intestinal-type sinonasal adenocarcinoma or myoepithelial carcinoma. Virchows Arch. https://doi.org/10.1007/s00428-023-03650-2
Agaimy A, Weichert W (2017) SMARCA4-deficient sinonasal carcinoma. Head Neck Pathol 11:541–545
pubmed: 28176137
pmcid: 5677070
doi: 10.1007/s12105-017-0783-4
Rooper LM, Uddin N, Gagan J et al (2020) Recurrent loss of SMARCA4 in sinonasal teratocarcinosarcoma. Am J Surg Pathol 44:1331–1339
pubmed: 32520761
doi: 10.1097/PAS.0000000000001508
Agaimy A, Jain D, Uddin N et al (2020) SMARCA4-deficient sinonasal carcinoma: a series of 10 cases expanding the genetic spectrum of SWI/SNF-driven sinonasal malignancies. Am J Surg Pathol 44:703–710
pubmed: 31934917
doi: 10.1097/PAS.0000000000001428
Contrera KJ, Shakibai N, Su SY et al (2023) Impact of clinical factors and treatments on SMARCB1 (INI-1)-Deficient Sinonasal Carcinoma. Otolaryngol Head Neck Surg 169:435–440
pubmed: 36856048
doi: 10.1002/ohn.310
Ngo C, Postel-Vinay S (2022) Immunotherapy for SMARCB1-deficient sarcomas: current evidence and future developments. Biomedicines 10(3):650. https://doi.org/10.3390/biomedicines10030650
Aspeslagh S, Morel D, Soria JC et al (2018) Epigenetic modifiers as new immunomodulatory therapies in solid tumours. Ann Oncol 29:812–824
pubmed: 29432557
doi: 10.1093/annonc/mdy050
Jo VY, Chau NG, Hornick JL et al (2017) Recurrent IDH2 R172X mutations in sinonasal undifferentiated carcinoma. Mod Pathol 30:650–659
pubmed: 28084339
doi: 10.1038/modpathol.2016.239
Dogan S, Chute DJ, Xu B et al (2017) Frequent IDH2 R172 mutations in undifferentiated and poorly-differentiated sinonasal carcinomas. J Pathol 242:400–408
pubmed: 28493366
pmcid: 5639875
doi: 10.1002/path.4915
Riobello C, Lopez-Hernandez A, Cabal VN et al (2020) IDH2 Mutation analysis in undifferentiated and poorly differentiated sinonasal carcinomas for diagnosis and clinical management. Am J Surg Pathol 44:396–405
pubmed: 31876581
doi: 10.1097/PAS.0000000000001420
Mito JK, Bishop JA, Sadow PM et al (2018) Immunohistochemical detection and molecular characterization of IDH-mutant sinonasal undifferentiated carcinomas. Am J Surg Pathol 42:1067–1075
pubmed: 29683816
doi: 10.1097/PAS.0000000000001064
Chambers KJ, Lehmann AE, Remenschneider A et al (2015) Incidence and survival patterns of sinonasal undifferentiated carcinoma in the United States. J Neurol Surg B Skull Base 76:94–100
pubmed: 25844294
Amit M, Abdelmeguid AS, Watcherporn T et al (2019) Induction chemotherapy response as a guide for treatment optimization in sinonasal undifferentiated carcinoma. J Clin Oncol 37:504–512
pubmed: 30615549
pmcid: 6380524
doi: 10.1200/JCO.18.00353
Stein EM, DiNardo CD, Fathi AT et al (2021) Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. Blood 137:1792–1803
pubmed: 33024987
pmcid: 8020270
doi: 10.1182/blood.2020007233
Bishop JA, Ogawa T, Stelow EB et al (2013) Human papillomavirus-related carcinoma with adenoid cystic-like features: a peculiar variant of head and neck cancer restricted to the sinonasal tract. Am J Surg Pathol 37:836–844
pubmed: 23598962
pmcid: 3653997
doi: 10.1097/PAS.0b013e31827b1cd6
Bishop JA, Andreasen S, Hang JF et al (2017) HPV-related multiphenotypic sinonasal carcinoma: an expanded series of 49 cases of the tumor formerly known as HPV-related carcinoma with adenoid cystic carcinoma-like features. Am J Surg Pathol 41:1690–1701
pubmed: 28877065
pmcid: 5680105
doi: 10.1097/PAS.0000000000000944
Rodarte AI, Parikh AS, Gadkaree SK et al (2019) Human papillomavirus related multiphenotypic sinonasal carcinoma: report of a case with early and progressive metastatic disease. J Neurol Surg Rep 80:e41–e43
pubmed: 31737465
pmcid: 6855919
doi: 10.1055/s-0039-3399571
Persson M, Andren Y, Mark J et al (2009) Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci U S A 106:18740–18744
pubmed: 19841262
pmcid: 2773970
doi: 10.1073/pnas.0909114106
Fujii K, Murase T, Beppu S et al (2017) MYB, MYBL1, MYBL2 and NFIB gene alterations and MYC overexpression in salivary gland adenoid cystic carcinoma. Histopathology 71:823–834
pubmed: 28594149
doi: 10.1111/his.13281
Persson M, Andren Y, Moskaluk CA et al (2012) Clinically significant copy number alterations and complex rearrangements of MYB and NFIB in head and neck adenoid cystic carcinoma. Genes Chromosom Cancer 51:805–817
pubmed: 22505352
doi: 10.1002/gcc.21965
Steiner P, Andreasen S, Grossmann P et al (2018) Prognostic significance of 1p36 locus deletion in adenoid cystic carcinoma of the salivary glands. Virchows Arch 473:471–480
pubmed: 29619555
doi: 10.1007/s00428-018-2349-6
Mathew EP, Todorovic E, Truong T et al (2022) Metatypical adenoid cystic carcinoma: a variant showing prominent squamous differentiation with a predilection for the sinonasal tract and skull base. Am J Surg Pathol 46:816–822
pubmed: 34864773
doi: 10.1097/PAS.0000000000001850
Weinreb I, Rooper LM, Dickson BC et al (2023) Adenoid cystic carcinoma with striking tubular hypereosinophilia: a unique pattern associated with nonparotid location and both canonical and novel EWSR1::MYB and FUS::MYB fusions. Am J Surg Pathol 47:497–503
pubmed: 36920022
doi: 10.1097/PAS.0000000000002023
Ho AS, Kannan K, Roy DM et al (2013) The mutational landscape of adenoid cystic carcinoma. Nat Genet 45:791–798
pubmed: 23685749
pmcid: 3708595
doi: 10.1038/ng.2643
Ho AS, Ochoa A, Jayakumaran G et al (2019) Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma. J Clin Invest 129:4276–4289
pubmed: 31483290
pmcid: 6763222
doi: 10.1172/JCI128227
Miller LE, Au V, Mokhtari TE, Goss D, Faden DL, Varvares MA (2022) A contemporary review of molecular therapeutic targets for adenoid cystic carcinoma. Cancers (Basel) 14(4):992. https://doi.org/10.3390/cancers14040992
Ferrarotto R, Mishra V, Herz E et al (2022) AL101, a gamma-secretase inhibitor, has potent antitumor activity against adenoid cystic carcinoma with activated NOTCH signaling. Cell Death Dis 13:678
pubmed: 35931701
pmcid: 9355983
doi: 10.1038/s41419-022-05133-9
Siqueira JM, Mitani Y, Hoff CO et al (2023) Analysis of B7–H4 expression across salivary gland carcinomas reveals adenoid cystic carcinoma-specific prognostic relevance. Mod Pathol 37:100371
pubmed: 38015043
doi: 10.1016/j.modpat.2023.100371
Ferrarotto R, Mitani Y, McGrail DJ et al (2021) Proteogenomic analysis of salivary adenoid cystic carcinomas defines molecular subtypes and identifies therapeutic targets. Clin Cancer Res 27:852–864
pubmed: 33172898
doi: 10.1158/1078-0432.CCR-20-1192
Wang X, Bledsoe KL, Graham RP et al (2014) Recurrent PAX3-MAML3 fusion in biphenotypic sinonasal sarcoma. Nat Genet 46:666–668
pubmed: 24859338
pmcid: 4236026
doi: 10.1038/ng.2989
Fritchie KJ, Jin L, Wang X et al (2016) Fusion gene profile of biphenotypic sinonasal sarcoma: an analysis of 44 cases. Histopathology 69:930–936
pubmed: 27454570
doi: 10.1111/his.13045
Le Loarer F, Laffont S, Lesluyes T et al (2019) Clinicopathologic and molecular features of a series of 41 biphenotypic sinonasal sarcomas expanding their molecular spectrum. Am J Surg Pathol 43:747–754
pubmed: 30829729
pmcid: 8261894
doi: 10.1097/PAS.0000000000001238
Nichols MM, Alruwaii F, Chaaban M et al (2023) Biphenotypic sinonasal sarcoma with a novel PAX3::FOXO6 fusion: a case report and review of the literature. Head Neck Pathol 17:259–264
pubmed: 36169791
doi: 10.1007/s12105-022-01479-w
Kominsky E, Boyke AE, Madani D et al (2023) Biphenotypic sinonasal sarcoma: a case report and review of literature. Ear Nose Throat J 102:385–390
pubmed: 33813901
doi: 10.1177/0145561321999196
Bell D, Phan J, DeMonte F et al (2022) High-grade transformation of low-grade biphenotypic sinonasal sarcoma: radiological, morphophenotypic variation and confirmatory molecular analysis. Ann Diagn Pathol 57:151889
pubmed: 35030392
doi: 10.1016/j.anndiagpath.2021.151889
Hasnie S, Glenn C, Peterson JEG et al (2022) High-grade biphenotypic sinonasal sarcoma: a case report. J Neurol Surg Rep 83:e105–e109
pubmed: 36110919
pmcid: 9470382
doi: 10.1055/s-0042-1755599
Meyer A, Klubickova N, Mosaieby E et al (2023) Biphenotypic sinonasal sarcoma with PAX3::MAML3 fusion transforming into high-grade rhabdomyosarcoma: report of an emerging rare phenomenon. Virchows Arch 482:777–782
pubmed: 36719455
pmcid: 10067655
doi: 10.1007/s00428-023-03501-0
Smith BC, Ellis GL, Meis-Kindblom JM et al (1995) Ectomesenchymal chondromyxoid tumor of the anterior tongue. Nineteen cases of a new clinicopathologic entity. Am J Surg Pathol 19:519–530
pubmed: 7726361
doi: 10.1097/00000478-199505000-00003
Bubola J, Hagen K, Blanas N et al (2021) Expanding awareness of the distribution and biologic potential of ectomesenchymal chondromyxoid tumor. Head Neck Pathol 15:319–322
pubmed: 32372271
doi: 10.1007/s12105-020-01169-5
Argyris PP, Bilodeau EA, Yancoskie AE et al (2016) A subset of ectomesenchymal chondromyxoid tumours of the tongue show EWSR1 rearrangements and are genetically linked to soft tissue myoepithelial neoplasms: a study of 11 cases. Histopathology 69:607–613
pubmed: 27010880
doi: 10.1111/his.12973
Dickson BC, Antonescu CR, Argyris PP et al (2018) Ectomesenchymal chondromyxoid tumor: a neoplasm characterized by recurrent RREB1-MKL2 fusions. Am J Surg Pathol 42:1297–1305
pubmed: 29912715
pmcid: 6133728
doi: 10.1097/PAS.0000000000001096
Agaimy A, Din NU, Dermawan JK et al (2023) RREB1::MRTFB fusion-positive extra-glossal mesenchymal neoplasms: a series of five cases expanding their anatomic distribution and highlighting significant morphological and phenotypic diversity. Genes Chromosom Cancer 62:5–16
pubmed: 35763541
doi: 10.1002/gcc.23082
Dahlen A, Fletcher CD, Mertens F et al (2004) Activation of the GLI oncogene through fusion with the beta-actin gene (ACTB) in a group of distinctive pericytic neoplasms: pericytoma with t(7;12). Am J Pathol 164:1645–1653
pubmed: 15111311
pmcid: 1615655
doi: 10.1016/S0002-9440(10)63723-6
Papke DJ Jr, Dickson BC, Oliveira AM et al (2023) Distinctive nested glomoid neoplasm: clinicopathologic analysis of 20 cases of a mesenchymal neoplasm with frequent GLI1 alterations and indolent behavior. Am J Surg Pathol 47:12–24
pubmed: 36395474
doi: 10.1097/PAS.0000000000001979
Agaram NP, Zhang L, Sung YS et al (2019) GLI1-amplifications expand the spectrum of soft tissue neoplasms defined by GLI1 gene fusions. Mod Pathol 32:1617–1626
pubmed: 31189998
pmcid: 6821565
doi: 10.1038/s41379-019-0293-x
Parrack PH, Marino-Enriquez A, Fletcher CDM et al (2023) GLI1 Immunohistochemistry distinguishes mesenchymal neoplasms with GLI1 alterations from morphologic mimics. Am J Surg Pathol 47:453–460
pubmed: 36693363
doi: 10.1097/PAS.0000000000002018
Machado I, Agaimy A, Giner F, Navarro S, Michal M, Bridge J, Claramunt R, López-Guerrero JA, Alcacer J, Linos K, Llombart-Bosch A (2023) The value of GLI1 and p16 immunohistochemistry in the premolecular screening for GLI1-altered mesenchymal neoplasms. Virchows Arch. https://doi.org/10.1007/s00428-023-03687-3
Xu B, Chang K, Folpe AL et al (2020) Head and neck mesenchymal neoplasms with GLI1 gene alterations: a pathologic entity with distinct histologic features and potential for distant metastasis. Am J Surg Pathol 44:729–737
pubmed: 31934916
pmcid: 7225037
doi: 10.1097/PAS.0000000000001439
Antonescu CR, Agaram NP, Sung YS et al (2018) A distinct malignant epithelioid neoplasm with GLI1 gene rearrangements, frequent S100 protein expression, and metastatic potential: expanding the spectrum of pathologic entities with ACTB/MALAT1/PTCH1-GLI1 fusions. Am J Surg Pathol 42:553–560
pubmed: 29309307
pmcid: 5844813
doi: 10.1097/PAS.0000000000001010
WHO Classification of Tumours Editorial Board. Soft tissue and bone tumours. Lyon (France): International Agency for Research on Cancer; 2020. (WHO classification of tumours series, 5th edn, vol 3). https://publications.iarc.fr/588
Leiner J, Le Loarer F (2020) The current landscape of rhabdomyosarcomas: an update. Virchows Arch 476:97–108
pubmed: 31696361
doi: 10.1007/s00428-019-02676-9
Mosquera JM, Sboner A, Zhang L et al (2013) Recurrent NCOA2 gene rearrangements in congenital/infantile spindle cell rhabdomyosarcoma. Genes Chromosom Cancer 52:538–550
pubmed: 23463663
doi: 10.1002/gcc.22050
Alaggio R, Zhang L, Sung YS et al (2016) A molecular study of pediatric spindle and sclerosing rhabdomyosarcoma: identification of novel and recurrent VGLL2-related fusions in infantile cases. Am J Surg Pathol 40:224–235
pubmed: 26501226
pmcid: 4712098
doi: 10.1097/PAS.0000000000000538
Agaimy A, Dermawan JK, Leong I et al (2022) Recurrent VGLL3 fusions define a distinctive subset of spindle cell rhabdomyosarcoma with an indolent clinical course and striking predilection for the head and neck. Genes Chromosom Cancer 61:701–709
pubmed: 35766997
doi: 10.1002/gcc.23083
Cyrta J, Gauthier A, Karanian M et al (2021) Infantile rhabdomyosarcomas with VGLL2 rearrangement are not always an indolent disease: a study of 4 aggressive cases with clinical, pathologic, molecular, and radiologic findings. Am J Surg Pathol 45:854–867
pubmed: 33949344
doi: 10.1097/PAS.0000000000001702
Watson S, Perrin V, Guillemot D et al (2018) Transcriptomic definition of molecular subgroups of small round cell sarcomas. J Pathol 245:29–40
pubmed: 29431183
doi: 10.1002/path.5053
Le Loarer F, Cleven AHG, Bouvier C et al (2020) A subset of epithelioid and spindle cell rhabdomyosarcomas is associated with TFCP2 fusions and common ALK upregulation. Mod Pathol 33:404–419
pubmed: 31383960
doi: 10.1038/s41379-019-0323-8
Dehner CA, Broski SM, Meis JM et al (2023) Fusion-driven spindle cell rhabdomyosarcomas of bone and soft tissue: a clinicopathologic and molecular genetic study of 25 cases. Mod Pathol 36:100271
pubmed: 37422156
doi: 10.1016/j.modpat.2023.100271
Brunac AC, Laprie A, Castex MP et al (2020) The combination of radiotherapy and ALK inhibitors is effective in the treatment of intraosseous rhabdomyosarcoma with FUS-TFCP2 fusion transcript. Pediatr Blood Cancer 67:e28185
pubmed: 31965718
doi: 10.1002/pbc.28185
Valerio E, Furtado Costa JL, Perez Fraile NM et al (2023) Intraosseous spindle cell/epithelioid rhabdomyosarcoma with tfcp2 rearrangement: a recent recognized subtype with partial response to alectinib. Int J Surg Pathol 31:861–865
pubmed: 36474403
doi: 10.1177/10668969221140397
Bridge JA, Fidler ME, Neff JR et al (1999) Adamantinoma-like Ewing’s sarcoma: genomic confirmation, phenotypic drift. Am J Surg Pathol 23:159–165
pubmed: 9989842
doi: 10.1097/00000478-199902000-00004
Rooper LM, Bishop JA (2020) Soft tissue special issue: Adamantinoma-like Ewing sarcoma of the head and neck: a practical review of a challenging emerging entity. Head Neck Pathol 14:59–69
pubmed: 31950471
pmcid: 7021882
doi: 10.1007/s12105-019-01098-y
Agaimy A, Baneckova M, De Almeida J et al (2023) Recurrent EWSR1::COLCA2 fusions define a novel sarcoma with spindle/round cell morphology and strong predilection for the sinonasal tract. Am J Surg Pathol 47:361–369
pubmed: 36580038
doi: 10.1097/PAS.0000000000002000
Koshyk O, Dehner CA, van den Hout MFCM, Bempt IV, Sciot R, Huang HY, Agaimy A, Din NU, Klubíčková N, Mosaieby E, Skálová A, Michalová K, Schöffski P, Oliveira AM, Halling KC, Gupta S, Gross JM, Nin JWM, Michal M, Folpe AL, Kosemehmetoglu K, Torres-Mora J, Michal M (2023) EWSR1::POU2AF3(COLCA2) sarcoma: an aggressive, polyphenotypic sarcoma with a head and neck predilection. Mod Pathol 36(12):100337. https://doi.org/10.1016/j.modpat.2023.100337
Hiemenz MC, Kaur J, Kuang Z et al (2023) POU2AF3-rearranged sarcomas: a novel tumor defined by fusions of EWSR1 or FUS to a gene formerly designated COLCA2. Genes Chromosom Cancer 62:460–470
pubmed: 36862145
doi: 10.1002/gcc.23136
Yoshida A, Arai Y, Satomi K et al (2022) Identification of novel SSX1 fusions in synovial sarcoma. Mod Pathol 35:228–239
pubmed: 34504309
doi: 10.1038/s41379-021-00910-x